TARS FY2025 SEC EDGAR DEF 14A #110 of 168 in industry

Tarsus Pharmaceuticals, Inc. CEO pay ratio

The CEO earned $6.6M in FY2025 against median worker pay of $251,525 · Chemicals & Pharmaceuticals.

Chemicals & Pharmaceuticals peers All rankings
State
DE
Filing date
2026-04-28
Industry
Chemicals & Pharmaceuticals
Industry rank
#110/168

Data updated August 2026

Subscribe to Tarsus Pharmaceuticals, Inc. CEO pay filing updates (RSS)

CEO-to-worker pay ratio
26:1
Below Average (Scale: 0–1000:1)
CEO pay
$6.6M
Median worker
$251,525

Answer first

Tarsus Pharmaceuticals, Inc.'s FY2025 CEO total of $6.6M ranks #795 of 1,423 complete filings; its 26:1 pay ratio ranks #1163. Dollar rank is not ratio rank.

According to the same FY2025 complete-filing cohort used on the rankings boards (CEO total, median worker, and ratio all present). Median worker pay is $251,525. Industry placement uses the FY2025 SIC-28 peer cohort (# 110 of 168, 35th percentile - below the industry median pay ratio). Figures come from Section 953(b) Dodd-Frank DEF 14A disclosures - not estimates. View all Chemicals & Pharmaceuticals companies.

Dollar rank
#795
$6.6M of 1,423 FY2025
Ratio rank
#1163
26:1 of 1,423
Industry pct
35th
below the industry median pay ratio

How Tarsus Pharmaceuticals, Inc. ranks nationally

Tarsus Pharmaceuticals, Inc. CEO pay vs. every FY2025 complete filing

Total CEO compensation, the full national distribution, this company marked

$6,617,979 44th percentile higher than 44% of 1,423 companies

$0–$2,500,000: 304 companies (21%). Below this entry. $2,500,000–$5,000,000: 182 companies (13%). Below this entry. $5,000,000–$7,500,000: 208 companies (15%). This entry sits in this band. $7,500,000–$10,000,000: 192 companies (13%). Above this entry. $10,000,000–$12,500,000: 139 companies (10%). Above this entry. $12,500,000–$15,000,000: 91 companies (6%). Above this entry. $15,000,000–$17,500,000: 88 companies (6%). Above this entry. $17,500,000–$20,000,000: 54 companies (4%). Above this entry. $20,000,000–$22,500,000: 24 companies (2%). Above this entry. $22,500,000–$25,000,000: 34 companies (2%). Above this entry. $25,000,000–$27,500,000: 24 companies (2%). Above this entry. $27,500,000–$30,000,000: 16 companies (1%). Above this entry. $30,000,000–$32,500,000: 10 companies (1%). Above this entry. $32,500,000–$35,000,000: 7 companies (0%). Above this entry. $35,000,000–$37,500,000: 9 companies (1%). Above this entry. $37,500,000–$40,000,000: 6 companies (0%). Above this entry. $40,000,000–$42,500,000: 1 companies (0%). Above this entry. $42,500,000–$45,000,000: 1 companies (0%). Above this entry. $45,000,000–$47,500,000: 6 companies (0%). Above this entry. $47,500,000–$50,000,000: 27 companies (2%). Above this entry. This company $0 $50M+ every complete-filing company, bucketed by value

Each bar is a $2500K-wide band; taller bars hold more companies. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source SEC DEF 14A Section 953(b) disclosures, PlainCEOPay extract · FY2025

Tarsus Pharmaceuticals, Inc. vs. Chemicals & Pharmaceuticals peers

CEO total pay ($6.6M) against pay ratio (26:1) for Tarsus Pharmaceuticals, Inc. (marked) and its 5 closest same-industry peers, against the Chemicals & Pharmaceuticals industry median on both axes.

Pay + gap both highContained pay, wide gapHigh pay, contained gapBelow peer norms on both160743.12187569.642143966241222.58268048.924.1:128.8:133.5:138.2:142.9:1CEO total payPay ratio (CEO : median worker)Tarsus Pharmaceuticals, Inc., CEO total pay: 6617979 · Pay ratio (CEO : median worker): 26:1Tarsus Pharmaceuticals, Inc.Harmony Biosciences Holdings, Inc., CEO total pay: 7899535 · Pay ratio (CEO : median worker): 26:1Harmony Biosciences Holdings, Inc.Siga Technologies Inc, CEO total pay: 3202425 · Pay ratio (CEO : median worker): 25:1Siga Technologies IncArdelyx, Inc., CEO total pay: 7796171 · Pay ratio (CEO : median worker): 25:1Ardelyx, Inc.Biohaven Ltd., CEO total pay: 529257 · Pay ratio (CEO : median worker): 25:1Biohaven Ltd.Sarepta Therapeutics, Inc., CEO total pay: 7708375 · Pay ratio (CEO : median worker): 25:1Sarepta Therapeutics, Inc.
Tarsus Pharmaceuticals, Inc. vs. Chemicals & Pharmaceuticals peers, plotted against the industry's $7.9M median CEO total and 42:1 median pay ratio.

Ratio bands among Chemicals & Pharmaceuticals peers

Exclusive CEO-to-median-worker bands across 153 complete latest-FY filings in SIC 28. Segments sum to the peer set, not this company's compensation pillar.

CEO Compensation Breakdown, FY2025

A component-level pay breakdown is not reported in Tarsus Pharmaceuticals, Inc.'s structured SEC pay-ratio disclosure. See our methodology →

Filing-year trail · Tarsus Pharmaceuticals, Inc.

Complete DEF 14A pay-ratio filings for this CIK across FY2024–2025. Year-over-year deltas compare adjacent filing years only; incomplete dollar rows are omitted (same completeness gate as the hero figures).

Latest ratio
26:1
FY2025
vs prior FY
-11:1
from FY2024 37:1
CEO $ YoY
-16%
$6.6M latest
Filings shown
2
FY2024–2025
Tarsus Pharmaceuticals, Inc. CEO total compensation, median worker pay, and pay ratio by fiscal year from SEC EDGAR DEF 14A.
FY CEO pay Δ pay Median worker Pay ratio Δ ratio
2024 $7.9M - $216,313 37:1 -
2025 $6.6M -16% $251,525 26:1 -11:1

Source: SEC EDGAR DEF 14A pay-ratio disclosures for CIK 1819790, FY2024–2025. Adjacent-year deltas only.

Industry Comparison - Chemicals & Pharmaceuticals

This Company's Ratio
26:1
Industry Median Ratio
42:1
Industry Median CEO Pay
$7.9M
This CEO's Pay
$6.6M
Companies in Industry
168
vs. Industry Median
Below
#110 of 168 by pay ratio in this industry View all companies in Chemicals & Pharmaceuticals →

Tarsus Pharmaceuticals, Inc.: MODEST · HEAVY pay ratio

Tarsus Pharmaceuticals, Inc.'s 26:1 ratio ranks #1163 of 1,423 FY2025 complete filings (lower third by ratio). the CEO earned 26× the median employee ($251,525) in FY2025.

Median employee $251,525 (ELITE-MED); MODEST · HEAVY stamps put about 26 median-wage years per CEO year.

CEO Total Pay

$6.6M

FY2025 Summary Compensation, below median

Pay Ratio

26:1

Below typical

Tarsus Pharmaceuticals, Inc. in the lower-ratio third

Tarsus Pharmaceuticals, Inc.'s 26:1 ratio ranks #1163 of 1,423 FY2025 complete filings (lower third by ratio). The structured pay-ratio disclosure reports the total without line-item components. Chemicals & Pharmaceuticals (SIC 28) median ratio is 42:1 across 168 FY2025 filers; Tarsus Pharmaceuticals, Inc.'s $6.6M CEO total is at or below the $7.9M industry median CEO pay.

Dollar rank #795 and ratio rank #1163 split - treat 26:1 as a disclosure, not a fairness score. Open Chemicals & Pharmaceuticals peers.

Key Data, FY2025

Total Compensation
$6.6M
Median Employee Pay
$251,525
Pay Ratio
26:1
Filing Date
2026-04-28

Company Info

Ticker
TARS
CIK
1819790
Industry
Chemicals & Pharmaceuticals
SIC Code
2836
State
DE
View SEC filings →
SEC EDGAR DEF 14A for CIK 1819790, FY2025. Informational only, not investment advice. Verify on EDGAR.

Read our methodology - how this data is sourced, computed, and verified. Tarsus Pharmaceuticals, Inc.'s 26:1 ratio ranks #1163 of 1,423 FY2025 complete filings (lower third by ratio).

Read with Tarsus Pharmaceuticals, Inc.

ABS(ceo_total_comp) peers first, then a SIC pole and a stamp-branched guide - not a fixed Related strip. This page stamps MODEST · HEAVY · ELITE-MED.

OUTFRONT Media Inc. · HEAVY

ABS(ceo_total_comp) peer at $6.6M (Δ $11K lighter vs Tarsus Pharmaceuticals, Inc.); MODEST · HIGH-MED vs this page's MODEST · HEAVY · ELITE-MED.
Innovative Industrial Properties Inc · HEAVY

ABS(ceo_total_comp) peer at $6.6M (Δ $17K heavier vs Tarsus Pharmaceuticals, Inc.); MODEST · ELITE-MED vs this page's MODEST · HEAVY · ELITE-MED.
LXP Industrial Trust · HEAVY

ABS(ceo_total_comp) peer at $6.6M (Δ $27K heavier vs Tarsus Pharmaceuticals, Inc.); MODEST · ELITE-MED vs this page's MODEST · HEAVY · ELITE-MED.
Installed Building Products, Inc. · HEAVY

ABS(ceo_total_comp) peer at $6.6M (Δ $29K lighter vs Tarsus Pharmaceuticals, Inc.); MID · PAR-MED vs this page's MODEST · HEAVY · ELITE-MED.
Harmony Biosciences Holdings, Inc. (SIC 28 pole)

Harmony Biosciences Holdings, Inc. stamps MODEST · HEAVY nearest in-SIC by ABS(pay_ratio) to Tarsus Pharmaceuticals, Inc.'s MODEST filing.
National dual ranks · #795/#1163

Tarsus Pharmaceuticals, Inc.'s FY2025 package sits #795 by CEO dollars and #1163 by ratio under HEAVY · MODEST.
Ratio primer · MODEST

Tarsus Pharmaceuticals, Inc.'s MODEST stamp sits in the lower Item 402(u) band - start with how the ratio is disclosed before comparing peers.
Data sourced from SEC EDGAR DEF 14A for Tarsus Pharmaceuticals, Inc. (CIK 1819790), FY2025. See our methodology. Aggregated by PlainCEOPay as of August 2026.

Data currency: Executive compensation from SEC EDGAR DEF 14A proxy statements through fiscal year 2025, compiled and last refreshed August 2026. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.